M. Beeram

1.1k total citations
48 papers, 860 citations indexed

About

M. Beeram is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Beeram has authored 48 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 17 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Beeram's work include HER2/EGFR in Cancer Research (17 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Cancer Treatment and Pharmacology (10 papers). M. Beeram is often cited by papers focused on HER2/EGFR in Cancer Research (17 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Cancer Treatment and Pharmacology (10 papers). M. Beeram collaborates with scholars based in United States, South Korea and Australia. M. Beeram's co-authors include Qing Tan, Douglas Russell, Linda A. deGraffenried, Amita Patnaik, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Shanu Modi, Sandhya Girish, Jay Tibbitts and Jonathan C. Trent and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

M. Beeram

47 papers receiving 840 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Beeram United States	16	452	406	304	169	165	48	860
Khoi Chu United States	15	468 1.0×	432 1.1×	218 0.7×	188 1.1×	66 0.4×	22	869
Nishan Tchekmedyian United States	10	522 1.2×	297 0.7×	400 1.3×	172 1.0×	73 0.4×	17	795
Sue-Hwa Lin United States	16	638 1.4×	535 1.3×	486 1.6×	257 1.5×	189 1.1×	23	1.2k
Robert N. Raju United States	16	667 1.5×	284 0.7×	241 0.8×	178 1.1×	181 1.1×	30	985
S-A. Im South Korea	18	799 1.8×	324 0.8×	454 1.5×	242 1.4×	163 1.0×	85	1.1k
Dina Leitão Portugal	14	673 1.5×	434 1.1×	193 0.6×	296 1.8×	129 0.8×	28	1.0k
Emmy D.G. Fleuren Netherlands	17	368 0.8×	497 1.2×	307 1.0×	108 0.6×	56 0.3×	25	871
Simon Vyse United Kingdom	15	489 1.1×	532 1.3×	525 1.7×	219 1.3×	71 0.4×	17	1.1k
Yozo Kawano Japan	19	435 1.0×	657 1.6×	331 1.1×	362 2.1×	93 0.6×	28	1.2k
Yasuyo Ohi Japan	21	635 1.4×	314 0.8×	177 0.6×	474 2.8×	142 0.9×	60	1.2k

Countries citing papers authored by M. Beeram

Since Specialization

Citations

This map shows the geographic impact of M. Beeram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Beeram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Beeram more than expected).

Fields of papers citing papers by M. Beeram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Beeram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Beeram. The network helps show where M. Beeram may publish in the future.

Co-authorship network of co-authors of M. Beeram

This figure shows the co-authorship network connecting the top 25 collaborators of M. Beeram. A scholar is included among the top collaborators of M. Beeram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Beeram. M. Beeram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tap, William D., Gregory M. Coté, Howard A. Burris, et al.. (2025). Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. Clinical Cancer Research. 31(11). 2108–2114. 1 indexed citations

Elimova, Elena, Sun Young Rha, Rachel Goodwin, et al.. (2025). 303MO Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2-expressing metastatic breast cancer (mBC): Final results of a phase I trial. ESMO Open. 10. 104875–104875. 1 indexed citations

Jhaveri, Komal, X. Cynthia, Elgene Lim, et al.. (2023). 383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. Annals of Oncology. 34. S338–S339. 9 indexed citations

Klempner, Samuel J., M. Beeram, Dhanusha Sabanathan, et al.. (2021). 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. Annals of Oncology. 32. S450–S450. 20 indexed citations

Patnaik, Amita, Glen J. Weiss, Drew Rasco, et al.. (2021). Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial. Cancer Chemotherapy and Pharmacology. 89(1). 93–103. 14 indexed citations

Lim, Elgene, M. Beeram, Amy Prawira, et al.. (2021). Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer. Cancer Research. 81(4_Supplement). OT–9. 3 indexed citations

Beeram, M., E.P. Hamilton, Mariela Blum Murphy, et al.. (2017). Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. Annals of Oncology. 28. v82–v82. 4 indexed citations

Beeram, M., Sara M. Tolaney, J. Thaddeus Beck, et al.. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 27. vi556–vi556. 8 indexed citations

Patnaik, Amita, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 78(3). 491–500. 4 indexed citations

10.

McCaffery, Ian, Ginna G. Laport, Andrew Hotson, et al.. (2016). Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers. Annals of Oncology. 27. vi124–vi124. 6 indexed citations

11.

Harb, Wael A., Alex A. Adjei, M. Beeram, et al.. (2016). Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2518–2518. 1 indexed citations

12.

Patnaik, Amita, Anthony W. Tolcher, M. Beeram, et al.. (2015). Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 76(3). 587–595. 37 indexed citations

13.

Papadopoulos, K., et al.. (2014). 96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifen. European Journal of Cancer. 50. 35–35. 1 indexed citations

14.

Harb, Wael A., Christopher H. Lieu, M. Beeram, et al.. (2014). A First-In-Human Study Evaluating the Safety and Pharmacology of Mm-151, a Novel Oligoclonal Anti-Egfr Antibody Combination in Patients with Refractory Solid Tumors. Annals of Oncology. 25. iv152–iv152. 1 indexed citations

15.

Saif, Muhammad Wasif, John Sarantopoulos, Amita Patnaik, et al.. (2011). Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(6). 1565–1573. 17 indexed citations

16.

Beeram, M., et al.. (2010). A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.. Journal of Clinical Oncology. 28(15_suppl). TPS169–TPS169. 13 indexed citations

17.

Chiorean, E. Gabriela, et al.. (2009). EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 27(15_suppl). 2564–2564. 24 indexed citations

18.

Hoff, Daniel D. Von, M. Beeram, Januario E. Castro, et al.. (2007). Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor. Molecular Cancer Therapeutics. 6. 1 indexed citations

19.

Beeram, M., et al.. (2007). Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Annals of Oncology. 18(8). 1323–1328. 140 indexed citations

20.

Patnaik, Amita, Kyriakos P. Papadopoulos, M. Beeram, et al.. (2007). A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. Journal of Clinical Oncology. 25(18_suppl). 3512–3512. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact